Inventiva Pharma is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.
Inventiva Pharma has raised $120.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Inventiva Pharma's investors include European Investment Bank, BlackRock, AbbVie, Samsara BioCapital, Sofinnova Partners.
Inventiva Pharma is headquartered in Daix, France.
Inventiva Pharma is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.
Inventiva Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Inventiva Pharma — Funding & Investors." VCBacked, June 2, 2026, https://www.vcbacked.co/company/inventiva-pharma. Accessed September 29, 2026.
VCBacked. (2026). Inventiva Pharma — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/inventiva-pharma
{{cite web |title=Inventiva Pharma — Funding & Investors |url=https://www.vcbacked.co/company/inventiva-pharma |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated